TCL CSOT Showcases World-First Mobile Display Innovations at MWC 2025
BARCELONA, Spain, March 4, 2025 /PRNewswire/ -- TCL CSOT, a global leader in display technology for over 15 years, showcased multiple world-first mobile display innovations at MWC 2025. As a part of the recently-launched TCL CSOT APEX brand, these solutions epitomize APEX's four pillars–pleasant display experience, reliable vision health, sustainable and low carbon, and unlimited future imagination–to bring sublime visual experiences to future smart devices.
"We must always stay at the forefront of innovation to deliver the best possible visual experiences to consumers," said Jun Zhao, Chief Executive Officer of TCL CSOT. "TCL CSOT's world-class showcase at MWC 2025 is a prime example of uncompromising display technology in both image quality and sustainability, guided by our APEX brand. As the ever-evolving demand for new visual experiences drives us toward new frontiers, we are dedicated to embracing our users' feedback and meeting their needs."
The World's First Camera-Under-Panel OLED Display (14")
TCL CSOT's 14-inch 4K PureSight Pro OLED display is the world's first laptop screen to use the Camera-Under-Panel (CUP) technology. By eliminating cutouts or notches of the webcam, users can work and play with fewer distractions.
Featured in the Lenovo Yoga Slim 9i laptop in a stunning 98% screen-to-body ratio, the PureSight Pro display offers 4K resolution, a 120Hz refresh rate, and exceptional color accuracy across full professional color gamuts. This also marks the first time TCL CSOT has applied its FMM OLED technology in mid-sized displays.
The World's First Lowest Driver Low-Power Screen (6.36")
This display is optimized for outstanding visuals without rapidly draining battery life in mobile devices. TCL CSOT's latest multiple frequency partition technology divides the display into up to three sections, each supporting different refresh rates. Combined with its innovative CMOS circuit design, the display reduces the overall IC power consumption by up to 31%.
TCL CSOT WQHD 120Hz Circular Polarizer Eye-Protection Display (6.67")
TCL CSOT's 6.67-inch WQHD eye protection display adopts a circularly polarized light technology that reduces glare, enhances contrast, and improves screen visibility in bright sunlight or when wearing sunglasses. It also incorporates global DC dimming technology, which significantly reduces screen flickering and minimizes eye strain.
The World's First MP Multiple Frequency Partitioned OLED Display (6.73")
Combining exceptional visual fidelity with eye care, TCL CSOT's multiple frequency partition technology allows this display to support three partitions simultaneously, reducing its driver IC power consumption by up to 20%. It achieves a 96% screen-to-body ratio, enabling mobile devices with thinner bezels. Furthermore, it's ultra-bright with an APL brightness of 3,200 nits, and features flicker-free 1,920Hz PWM dimming. This display has been integrated into the newly announced Xiaomi 15 Pro smartphone.
TCL CSOT Moth-Eye Biomimetic Eye Care Tablet Display (12.1")
TCL CSOT's 12.1-inch moth-eye biomimetic eye care tablet display incorporates anti-glare, anti-reflective, anti-fingerprint, and anti-microbial features to enhance both visual clarity and cleanliness. Delivering a viewing experience that closely mimics natural light, it features depolarization technology, allowing users to see screen content clearly even while wearing sunglasses. Additionally, its moth-eye-inspired nanostructure disperses light to offer a comfortable viewing experience in bright environments. And with a low blue light ratio of under 20%, it reduces eye strain during prolonged use.
The World's First 4K 144Hz AI Tablet Display (13")
TCL CSOT's 13.0-inch 4K display delivers rich colors and sharp details in 4K resolution and an ultra-smooth 144Hz refresh rate. Its three-zone multiple frequency partition technology, combined with an advanced AI algorithm, dynamically adjusts the frequency-sharing strategy to optimize power consumption while ensuring smooth video performance, reducing power usage by 21% compared to traditional solutions. Plus, with a 240Hz or higher touch panel reporting rate, users can enjoy a responsive writing experience when using a stylus.
About TCL CSOT
Established in 2009, TCL China Star Optoelectronics Technology Co., Ltd. (TCL CSOT) is a leading global innovator in display technologies. Its LCD, OLED, and MLED technologies serve applications across TVs, mobile devices, tablets, laptops, monitors, automotive displays, VR/XR, and commercial displays. With multiple R&D facilities and 11 production lines in operation, TCL CSOT remains committed to delivering cutting-edge display solutions and fostering a dynamic, sustainable display solutions ecosystem. As a part of TCL's Worldwide Olympic Partnership through to 2032, TCL CSOT will provide a range of display solutions to enhance the Olympic experience.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcl-csot-showcases-world-first-mobile-display-innovations-at-mwc-2025-302392083.html
SOURCE TCL China Star Optoelectronics Technology
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Tech leader unveils groundbreaking laptop concept that runs on sunlight and folds flat like a book: 'Worth keeping an eye on'
Lenovo has been known to push the boundaries of laptop design, and its latest concept devices continue to deliver fresh innovations that include solar power. At Mobile World Congress 2025, the laptop maker revealed both the Lenovo ThinkBook Flip AI PC and Yoga Solar PC concepts, which could inform the next generation of consumer laptops. CNBC said that given the company's track record of bringing these innovative designs to market, "it's worth keeping an eye on what the Chinese technology giant is up to." The ThinkBook "codename Flip" AI PC, as the company called it, showed off an outward folding OLED display that can provide 18 inches of visual workspace or be folded over for a tablet-style interface. Workflows powered by artificial intelligence, split-screen multitasking, and smart workspace adaptation are being tested in this unique design. Sustainable power is also on the mind of Lenovo engineers, who worked up the Yoga Solar PC proof of concept to help capture the power of the sun to extend the device's runtime. This model includes a photovoltaic cell with 24% energy conversion efficiency, which is one of the best ratings available on the market, the company said. It's achieved through its Back Contact Cell technology, which places brackets and gridlines behind the solar cell for maximum absorption. Its Dynamic Solar Tracking system monitors the panel's current and voltage, working alongside the Solar-First Energy system for prioritizing the sun's rays for energy savings and stability. It can even generate power in low-light conditions while the PC is idle. The Yoga Solar PC can convert enough direct sunlight in 20 minutes to power up to one hour of video playback, according to the company. Measuring just 15 millimeters thin and weighing approximately 2.7 pounds, it's being called the world's first ultra-slim solar-powered PC. This improves upon Samsung's NC215S, which was reportedly the first laptop to include an integrated solar panel in 2011 and needed two hours of sunlight to run for one hour. Engineers and designers are realizing the potential of harnessing the sun's rays to power devices big and small across a variety of applications. What kind of solar tech would you be the most willing to use? Rooftop panels Community solar A portable solar generator None of the above Click your choice to see results and speak your mind. By leveraging renewable energy sources at every opportunity, we can more rapidly eliminate the use of dirty fuels and promote a cleaner, safer environment. Aptera's battery-powered electric vehicle includes solar panels on much of its exterior that help extend its runtime, while other companies have designed portable solar cells to help charge electric vehicles while parked. Lenovo has a track record of sustainable endeavors, championing repairs when possible to reduce waste, and offering cash for trade-ins so they can handle old devices more responsibly. Mary Jacques, Lenovo's executive director of Global ESG and Regulatory Compliance, told The Cool Down last year: "Our customers are really hungry for more and more information about not just the products that they're buying, but the impact that we can have on their sustainability journey." Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Dominion Post
3 hours ago
- Dominion Post
Hope Gas Morgantown pipeline makes progress: A visit to construction sites
dbeard@ MORGANTOWN – Hope Gas is making steady progress on its Morgantown Connector Project – a new 30-mile pipeline from Wadestown to Morgantown – and took The Dominion Post on a visit to several sites along the route last week. A section of pipeline is buried and awaits reclamation. Brittany McDaniel, Hope's director of Engineering Project Management, and Colin Mitchell, project manager for contractor Apex Pipeline Services, led the tour. Jonell Carver, Hope's chief operating office, Chris Hendrick, Hope vice president for Reliability, and Jason Barnette, with Hope's land department, also joined. Nitro-based Apex is the contractor for the 10-mile 'spread' leading into Morgantown. Charleston-based Ace Pipeline won the contracts for the two other 10-mile spreads. Apex started cutting trees in January, McDaniel said, and expects to be nearly done with its work by the end of July into August – ahead of schedule. Ace is also ruining ahead of schedule. The line is planned to go into service Nov. 1, at the start of winter heating season when demand picks up. Additional restoration and cleanup will continue into 2026. Another view of the buried section. Hope is building the pipeline to meet increased demand for natural gas in the Morgantown area. A second line will also provide redundancy – should there ever be an issue with the existing line. But Hope also said during our Wednesday tour that one of its missions it to create West Virginia jobs. Mitchell said Apex is employing about 150 people for its spread, while Ace has about 300 on its two sections. McDaniel said each spread also requires 20-30 Hope inspectors and support staff. And that doesn't count service jobs – dump trucks and delivery trucks – and indirect jobs for hotels, restaurants and the various suppliers, Mitchell said. We visited three sites in various stages of development. At one, outside Westover, two big yellow shovels sat at the bottom of a hill. A line of 16-inch pipe ran down the cleared right of way. Metal support structures keep the pipe off the ground. A section of reclaimed hillside. At the next site, also outside Westover, the right of way runs up and down more hills and the pipe is buried. Mitchell said the line must have a minimum of 3 feet of coverage, but there's usually more. And the original ground goes back on top of that, so the line is generally about 6-7 feet below the surface. McDaniel noted that laying pipeline is different from running it along flatland. As West Virginia companies, both contractors have an advantage. 'They know how to handle this mountainous terrain.' The third site, out Fairmont Road and up Little Indian Creek Road near the Arkwright Mine, is already reclaimed. Grass is growing on the right of way running down the hill. They work with landowners, McDaniel said, to meet their needs and demand for specific types of grass, fencing, property line posts and so on. And while the original design ran as straight as possible, she said, they've adjusted the course for the realities on the ground – including the residents along the way. The second site was moved several hundred yards to avoid a new subdivision under construction. McDaniel estimated that the project right of way involved about 243 landowners. We've reported several times that Hope filed 31 condemnation suits – seeking eminent domain – in Monongalia County Circuit Court, and spoken with landowners unhappy with Hope's negotiations for compensation. A look at court records on Thursday showed 23 cases open and eight settled and closed. We asked McDaniel about those holdouts. 'We're working on that,' she said. Some are in the process of resolution and will be settled while some will be resolved by the court. Along with compensation for loss of land use, some landowners raised pipeline safety concerns to The Dominion Post. We also asked McDaniel about that. She said, 'As far as I'm concerned, pipelines are the safest form of [gas] transportation that there is.' She has lines across her land, she said, and described some of the safety measures they employ, including X-raying all the pipe welds and testing the lines to 1.5 times their operating pressure.
Yahoo
4 hours ago
- Yahoo
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, June 1, 2025 /PRNewswire/ -- Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.1 These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2—a prostate-specific antigen with minimal expression outside of the prostate. Pasritamig activates T-cells by binding to CD3 and directing them to KLK2- expressing tumor cells, engaging the body's immune system to specifically target these cancerous cells. This differentiated approach aims to deliver a targeted treatment for patients with advanced prostate cancer, while potentially reducing the high-grade toxicities historically associated with T-cell engagers. "These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer," said Capucine Baldini*, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author. "The data show a promising safety profile, with manageable adverse events and no AEs leading to treatment discontinuations or ICANS observed, with 40 percent of patients having no treatment-related AEs at all. Given the limited treatment options for mCRPC, these findings support further investigation of pasritamig and the role of KLK2-targeted T-cell therapies as a potential new approach for patients with aggressive disease." "Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven't responded well to previous treatments," said Jeff Infante, M.D., Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. "This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings." The Phase 1 first-in-human study (NCT04898634) evaluated 174 patients with ages ranging from 36 to 89 years old and on average having received four prior therapies (range 1-13). The recommended phase 2 dose (RP2D) of pasritamig was 3.5mg on day 1, 18mg on day 8, 300mg intravenously on day 15 and then once every six weeks. The RP2D safety group also included patients treated once every three weeks as the toxicity profiles were very similar. The RP2D efficacy group only included patients treated at the RP2D once every six weeks.1 Within the RP2D safety group (n=45), treated once every three or six weeks, 100 percent had previously received androgen receptor pathway inhibitors, 75.6 percent had undergone taxane chemotherapy, and 37.8 percent had been treated with Lutetium 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy.1 The most common treatment- related adverse events (TRAEs) were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3 TRAEs were infrequent with 4.4 percent of patients reporting transient AST/ALT increases and neutropenia. There were no dose-limiting toxicities reported. The favorable safety profile of the RP2D regimen enabled convenient outpatient administration on a patient-friendly, once-every-six-weeks schedule.1 Of the patients in the RP2D efficacy group (n=33), treated once every six weeks, 42.4 percent achieved a 50 percent or greater reduction in their prostate-specific antigen (PSA) levels with a median rPFS of 7.9 months (95 percent confidence interval [CI] 2.9, not estimable [NE]) and 21.2 percent of patients continuing therapy. Treatment with pasritamig showed durable disease control and rPFS that compares favorably to historical data in heavily pretreated patients with mCRPC.1 Metastatic castration-resistant prostate cancer occurs in a significant portion of prostate cancer patients, with many progressing despite initial therapies.2 Overall survival from diagnosis of mCRPC patients ranges from 13.5 to 31.6 months, and lower in patients who have progressed on therapy.3 Treatment options remain limited, underscoring the urgent need for safer and more effective therapies.4 About Pasritamig (JNJ-78278343)Pasritamig (JNJ-78278343) is an investigational T-cell-engaging bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T-cells. This approach is being evaluated in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. About Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.2 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.5 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15–36 months across the broader population.3,6 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with mCRPC being responsible for a substantial number of prostate cancer-related deaths. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of JNJ-78278343. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Source: Johnson & Johnson *Dr. Capucine Baldini has provided consulting, advisory, and speaking services to Johnson & Johnson; Dr. Baldini has not been paid for any media work. 1 Baldini, C., et al. Phase 1 Study Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer. 2025 American Society of Clinical Oncology Annual Meeting. June 2025.2 Scher, H. I., et al. (2016). "Treatment of castration-resistant prostate cancer: Current and future strategies." Nature Reviews Clinical Oncology, 13(10), 577-590.3 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-44 Ravi P, Mateo J, Lorente D, et al. Clinical prognostic factors and management of metastatic castration-resistant prostate cancer: a population-based study. PLoS One. 2015;10(10):e0139440. doi:10.1371/ Ryan, C. J., et al. (2015). "Abiraterone acetate in metastatic prostate cancer: A new era." Journal of Clinical Oncology, 33(10), 1051-1060.6 Kawahara, T., Saigusa, Y., Yoneyama, S. et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer 23, 214 (2023). Media contacts:Oncology Media Relations oncology_media_relations@ Investor contact:Lauren Johnsoninvestor-relations@ U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: SOURCE Johnson & Johnson Sign in to access your portfolio
